Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases
... uses a tiny silicone cup filled with any drug and
sealed to the outer surface (episclera) of the ... the sustained delivery of medicines for retinal and
vitreous diseases, according to a new report by ... Dr. Murphree is also Professor of Ophthalmology and
Pediatrics at the Keck School of Medicine of the ...
Regular Yoga Practice Is Associated With Mindful Eating
... yoga practice is associated with mindful eating, and
people who eat mindfully are less likely to be ... reported four years ago by Alan Kristal, Dr.P.H., and
colleagues, who found that regular yoga practice ... prevent middle-age spread in normal-weight people and
may promote weight loss in those who are ...
Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
LYON, France and
SWIFTWATER, Pa., Aug. 7 /PRNewswire/ -- Sanofi ... of the sanofi-aventis Group (EURONEXT: SAN and
NYSE: SNY ), announced today the company has submitted to the U.S. Food and
Drug Administration (FDA) a supplemental ...
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
... M.D., Ph.D., executive vice president of Research and
Development at Amgen. "These are the first ... events such as skin toxicity, hypomagnesemia and
Originally designed to compare ... findings when oxaliplatin-based chemotherapy and
an anti-EGFR antibody are combined.
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
... to successfully execute its business strategy and
as a result reported $669,000 of pro forma net ... ended the quarter with $637.5 million of cash and
remains on track to end 2009 with more than $550 ... of more than $145 million of pro forma net income and
a pro forma net operating loss in the low to mid ...
Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
... (GNF) to create a diabetes drug discovery and
development platform. The four-year program is one of the largest and
most comprehensive collaborations in the 40 year ... the agenda for diabetes research worldwide and
the largest charitable ...
Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
... treatment to a patient's cancerous tumor and
is rapidly becoming the treatment of choice for ... precise delivery, the surrounding healthy tissue and
critical organs are preferentially spared from high doses of radiation and
side effects may be reduced.
Unlike low ...
SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
... Oracle Siebel Clinical Trial Management System and
Oracle Adverse Events Reporting System.
... us manage critical tasks in clinical operations and
drug safety in an efficient and
globally compliant manner, thus providing our ...
Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
... bone mineral density (BMD) at the lumbar spine and
femoral neck (a common fracture site located in ... six months of therapy. The gains in lumbar spine and
femoral neck BMD were further increased in a ... therapy for a total of 12 months of treatment, and
at both time points, the changes were greater ...
NewCardio Announces Master Services Agreement With Dedicated Phase I
... (OTC Bulletin Board: NWCI) a cardiac diagnostic and
services company, today announced that Dedicated ... including a Core ECG laboratory for Thorough QT and
QTc studies, has signed a Master Services ... its customers.
Jason Bonanza, President and
CEO of Dedicated Phase I, commented, "We are ...
Labopharm files New Drug Submission with Health Canada for novel antidepressant
... Canada," said James R. Howard-Tripp, President and
Chief Executive Officer, Labopharm Inc. "We ... opportunity for our trazodone formulation and
we are currently in discussions with potential ... on data from five pivotal pharmacokinetic studies and
the positive results from a North American Phase ...
NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
... VLP vaccine to support human clinical studies and
stands ready to assist with additional public ... Mr. Jim Robinson, Vice President of Manufacturing and
Quality Operations at Novavax, commented, "Demonstration of our ability to construct and
produce GMP-quality influenza vaccine within 12 ...
2,500 Cases Completed With the Magnetic Irrigated Catheter
... of medicine at The Ohio State University and
an electrophysiologist at the Ross Heart Hospital ... arrhythmias in all four chambers of the heart and
across a broad spectrum of patients ranging from ... in patients with congenital heart defects and
patients with peripheral vascular occlusive ...
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
... as compared to a year ago. Total operating costs and
expenses were down 19% to $43.5 million in the ... For the first half of 2009, total operating costs and
expenses were down 28% to $83.5 million as ... pipeline," stated Howard W. Robin, President and
Chief Executive Officer of Nektar. "We completed ...
DNA Helps Reunite Children With Their Families
Arthur Eisenberg, Ph.D., professor and
chairman of the department of forensic and
investigative Genetics and
co-director of the UNT Center for Human ...
ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer
... -- ARUP Laboratories , a national clinical and
anatomic pathology reference laboratory and
a leader in innovative laboratory research and
development, supports the U.S. ...
Study Shows Brain Fitness can Save Medicare Billions
... brain fitness exercises can have a significant and
long lasting impact on healthcare costs and
outcomes, according to a study recently published ... trial funded by the National Institutes of Health and
known as the Advanced Cognitive Training for ...
CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research
... team to make a real difference to the diagnosis and
a disease that counts among the ... In total, more than 100 partners from
academia are involved in the projects, which are ... the
basis of 25% from industry, 25% from academia and
50% from the Dutch
About CTMM ...
Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
... LAUSANNE, Switzerland and
WOBURN, Massachusetts, August 4 /PRNewswire/ ... drugs that
target unmet medical needs, and
Mercury Therapeutics, Inc. (Mercury), a
privately ... exclusive license
agreement for the development and
commercialisation of Debio 0930, a small
Scientists Discover Origin of Malaria
... Ph.D., of the Global Viral Forecasting Initiative and
Stanford University, made the discovery, ... animals to humans, much the way that HIV, SARS and
swine flu originated.
"This discovery ... parasites had co-existed separately in human and
chimpanzee ancestors for the last 5 million ....
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
... patients with solid tumors (not including breast and
prostate cancer) or multiple myeloma.
Overall, the incidence of adverse events and
serious adverse events was consistent with what ... of osteonecrosis of the jaw (ONJ) were balanced and
infrequent in both treatment groups (10 patients ...
Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
... published earlier in the Journal of Hematology and
Oncology, 13 May 2009; Vol. 2, No.20, pp. 20-32. ... MDS (enrollment completion expected by year end), and
Severe Chronic Idiopathic Neutropenia. Reprints ... available from Telik.
Background on MDS and
MDS is a heterogeneous group of ...
Project Zero Delay Accelerates Drug's Path to Clinical Trial
WILMINGTON, Del., Aug. 3 /PRNewswire-FirstCall/ ... its first patient only two days after U.S. Food and
Drug Administration clearance of the experimental ... University of Texas M. D. Anderson Cancer Center and
pharmaceutical company AstraZeneca have reported ...
TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men
... two new publications on hormone therapies and
their effects on reducing the risks of ... that commonly support the heart, brain, kidneys and
cause blood clots, heart ...
Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention
... papers on a variety of cervical cancer issues and
topics that were the focus of its Forum " The ... may have on rates of cervical precancer and
cervical cancer screening, strategies to measure vaccine uptake and
obstacles surrounding separate screening for ...
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
... N.J., Aug. 3 /PRNewswire/ -- The U.S. Food and
Drug Administration approved INVEGA(R) ... injectable suspension for the acute and
maintenance treatment of schizophrenia in adults ... ability to think clearly, relate to others, and
distinguish between ...
Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
... in France. The study will examine dose levels and
regimens of ProLindac monotherapy in cancer ... data to support design of combinations studies, and
extend the safety database. Two ovarian cancer patients have been enrolled in the study to date, and
it is anticipated 6 to 12 patients will be ...
Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor
... OMER and
MIGDAL HA'EMEK, Israel, August 3 ... (TASE: MDGS) a leading developer of endoscopic and
medical devices, and
Tower Semiconductor, Ltd. (Nasdaq: TSEM , TASE: ...
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
... The Company also announced that the U.S.
Drug Administration (FDA) has accepted its treatment protocol for
velaglucerase alfa and
that Shire has begun its rolling submission of ... velaglucerase alfa program
from both a clinical and
regulatory perspective," said Sylvie ...
OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
... -- Cell Therapeutics, Inc. (CTI) (Nasdaq and
MTA: CTIC) announced results from a study ... the combination of OPAXIO (paclitaxel poliglumex) and
Alimta(R) (pemetrexed) was well tolerated and
resulted in median progression-free survival of ....
John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden
... 29 /PRNewswire/ -- Grammy-Award winning artist and
long-time (PRODUCT)RED supporter John Legend is ... they provide an innovative way for great brands and
great artists to come together to powerfully and
effectively fight AIDS in Africa," said Legend. ...
Online H1N1 Management: FairChoice Helps Schools Respond to Infectious Disease on Campus
... prevention, monitor the spread of infection, and
track vaccination compliance. FairChoice Health is the first and
only end-to-end service for vaccination compliance management specifically designed for colleges and
The enhancement of ...
GAA Calls on Secretary Clinton to Speak Out Against Gender-Based Violence During Her Africa Trip
... Clinton's decision to visit Africa next week and
her decision to focus attention during her visit on preventing conflict and
violence, including gender-based violence, on the African continent. Violence against women (VAW) and
violence against children (VAC) are issues in ...
Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
... at two US centers, as a blinded, randomized, and
placebo-controlled study, in 30 patients ... objective was to assess the safety, tolerability, and
pharmacokinetics of PSI-7851 after once-daily ... of -0.49 log(10) IU/mL, -0.61 log(10) IU/mL and
-1.01 log(10) IU/mL in patients receiving 50mg ...
British Woman Celebrates a Year of Living Cancer-Free
... a cancer treatment that changed her life -- and
made history to boot.
Ms. Scott, 54, was the ... of traditional treatments, including chemotherapy and
a bone marrow transplant, failed to keep her in ... felt fine immediately. I was going out to dinner and
things like that," Ms. Scott said. "It was really ...
Covance Receives Highest Level of Phase I Accreditation
... today announced that it has received standard and
supplementary accreditation for the conduct of clinical pharmacology in Europe by the Medicines and
Healthcare products Regulatory Agency (MHRA). ... process provides clinical trial volunteers and
sponsors with confidence that research ...
Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window
... FL, the data suggests that this treatment is safe and
potentially leads to improved outcomes for a ... Raul Nogueira, M.D., Assistant in Neurology and
Radiology at Massachusetts General Hospital -- ... the 237 study participants, 49 percent were males and
51 percent were females, with a mean (or average) ...
FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia
... (NYSE: SGP ) today announced that the U.S. Food and
Drug Administration (FDA) Psychopharmacologic ... (asenapine) sublingual tablets as effective and
safe for the acute treatment of manic or mixed ... associated with bipolar I disorder in adults and
in favor of use in acute treatment of ...
VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
... biologic pathway using an integrated and
innovative array of in vitro readouts and
advanced in vivo imaging technologies. The ... are expected to open up new areas of research and
potentially advance therapeutic approaches to key ...
New Powder Speeds Healing of Difficult Foot Wounds
... -- Foot complications, such as open wounds and
ulcers, can be one of the most difficult ailments ... of skin, is proving to speed the healing time and
reduce the amount of pain that a patient ... Meeting in Toronto, July 30 - August 2, 2009, and
will highlight the powder's unique ability to ...